心肌病基因变异和多基因风险评分在心房动:证据一个心房-第一个表型
Guilherme L da Rocha1, James Feiner2, Julieta Lazarte3
1Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada.
Journal of the American College of Cardiology
|February 18, 2026
概括
导致心肌病的遗传变异会增加心房动 (AF) 的风险,即使没有心力衰竭. 将遗传风险得分与这些变异结合起来,有助于预测心房与心室疾病的发展.
科学领域:
- 心血管遗传学 心血管遗传学
- 基因组学就是基因组学.
- 医学遗传学 医学遗传学
背景情况:
- 心房动 (AF) 是一种遗传性疾病,具有复杂的遗传基础.
- 了解AF和心肌病之间的遗传联系对于风险分层至关重要.
研究的目的:
- 调查心肌病引起变异对AF风险的影响.
- 评估多基因风险评分 (PRS) 在区分心房和心室疾病风险方面的有用性.
主要方法:
- 考克斯回归分析用于评估心肌病变体和AF之间的关联.
- 用于AF,扩张性心肌病 (DCM) 和多变性心肌病 (HCM) 的疾病特异性PRS被利用.
- 使用元分析和卡普兰-梅尔方法来评估累积发病率.
主要成果:
- 引起疾病的变异与AF风险增加1.73倍相关 (P<0.001).
- 在调整室内心肌病或心力衰竭 (调整HR:1.55) 后,这种关联仍然存在.
- 患有高风险变体和PRS的个体显示累积AF和心肌病风险显著增加.
结论:
- 与心肌病相关的遗传变异增加了AF风险,独立于明显的心室疾病或心力衰竭.
- 将疾病特异性PRS与这些变体相结合,有助于预测患上心房或心室疾病的可能性.
- 引起心肌病的基因可能对AF风险产生重大,往往相等或更大的影响.
更多相关视频
相关概念视频
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
Cardiomyopathy III: Hypertrophic Cardiomyopathy
540
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
540
Pharmacogenomics: Identification of New Drug Targets
25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
Principles of Pharmacogenetics: Types of Genetic Variants
22
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
22
Cardiomyopathy I: Introduction and Classification
645
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
645
Genome-wide Association Studies-GWAS
15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.8K


